On November 9, 2021 Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology reported that it will present two research posters on its HPK1 and STING programs at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting (SITC 2021) taking place on November 10 – 14, 2021, in Washington, DC (Press release, Ryvu Therapeutics, NOV 9, 2021, View Source [SID1234594919]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Ryvu will present a poster on novel, orally administered HPK1 inhibitors which exhibit nanomolar activity in an immunosuppressive environment. These small molecules have shown favorable PK profiles allowing for in vivo target engagement after oral administration, and hold promising potential as a treatment in a variety of solid tumor indications.
The second poster will highlight a novel small-molecule STING agonist, RVU-27065. Selective STING pathway activation with RVU-27065 allows for repolarization of immunosuppressive tumor-associated macrophages into a pro-inflammatory phenotype without a negative impact on T-cell function. With favorable drug-like properties and a good safety profile, RVU-27065 is a promising candidate for standalone treatment as well as targeted delivery as a payload for antibodies.
Both posters will be available online as of November 12, at 7 AM ET, and presented during the Poster Session on November 13, at the Walter E. Washington Convention Center in Washington, D.C.
Novel, orally administered HPK1 inhibitors demonstrate anti-tumor efficacy and enhanced immune response (Abstract ID: 752), Maciej Kujawa et al.
On-site presentation session: November 13, 2021, 7:00 AM – 8:30 PM, Poster Hall E
Characterization of RVU-27065 a novel small-molecule STING agonist suitable for systemic administration (Abstract ID: 764), Maciej Rogacki et al.
On-site presentation session: November 13, 2021, 7:00 AM – 8:30 PM, Poster Hall E
To view the abstracts, please visit: View Source